Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...

Other oral therapies for this are already available; notably, Amgen’s PDE4 inhibitor Otezla (apremilast) and Bristol Myers Squibb’s Tyk-2 inhibitor Sotyktu (deucravacitinib). So, Dice’s lead ...